Cargando…
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
Multiple sclerosis (MS) is a chronic and progressive neurological disease that is characterized by neuroinflammation, demyelination and neurodegeneration occurring from the earliest phases of the disease and that may be underestimated. MS patients accumulate disability through relapse-associated wor...
Autores principales: | Filippi, Massimo, Amato, Maria Pia, Centonze, Diego, Gallo, Paolo, Gasperini, Claudio, Inglese, Matilde, Patti, Francesco, Pozzilli, Carlo, Preziosa, Paolo, Trojano, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489547/ https://www.ncbi.nlm.nih.gov/pubmed/35608658 http://dx.doi.org/10.1007/s00415-022-11193-w |
Ejemplares similares
-
Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
por: Filippi, Massimo, et al.
Publicado: (2022) -
Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4
por: Centonze, Diego, et al.
Publicado: (2023) -
Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus
por: Filippi, Massimo, et al.
Publicado: (2021) -
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
por: Centonze, Diego, et al.
Publicado: (2021) -
Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)
por: Comi, Giancarlo, et al.
Publicado: (2017)